// App-Quantinova.ai

e14584 : A phase 1 clinical trial of a PSA/IL-2/GM-CSF containing prostate cancer vaccine in PSA defined biochemical recurrent prostate cancer patients.

Researchers

Presenter

  • Gregory A. Daniels

Principal Investigators

  • Michelle McKinney

  • Weg Ongkeko

  • Jessica Wang-Rodriguez

  • Kyoko Sakamoto

  • Robert Lange Elliott

  • Jonathan F. Head

Medical Centers

  • University of California, San Diego, Moores Cancer Center, La Jolla, CA

  • VA San Diego Healthcare System, San Diego, CA

  • VA Medical Center, San Diego, CA

  • Oncbiomune Pharmaceuticals, Baton Rouge, LA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

  • Solid malignancies

Biomarkers

  • Prostate specific antigen

  • Granulocyte-macrophage-colony stimulating factor

  • Interleukin-2

Drug/Treatment

  • CVac

  • GM-CSF

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT02058680

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved